For pharma, an oncology conference is an important opportunity to inform and engage healthcare providers on the newest knowledge, with the motivation to improve patient outcomes and improve adherence.
Conference coverage reports compile and advise on conference content, including newly discovered cancer targets, changes to standards of care and key clinical practices, competitor marketing strategies and messaging, and general conference takeaways. Oncology reports are primarily based on tumor type, compound, or mechanism of action.
1. Analysis of the Current Treatment Landscape
Conference coverage reports offer you an in-depth look into the current treatment landscape. They provide insight into drug management for all treatment modalities of cancer care, including surgery, radiologic intervention, and systemic agents. Quantitative analysis of how various drug therapies are utilized during different stages of cancer treatment is also covered in the reports.
In addition to a comprehensive assessment of market drugs, conference coverage reports summarize and highlight important clinical data that speak to current standard-of-care practices. Information about drug utilization is organized by line of therapy, by tumor type, and by biomarker segmentation.
2. Future Oncology Insights Focusing on Clinical Trials
Conference coverage reports rely on expert analysis to predict trends and future insight into the cancer sector by looking closely at ongoing clinical trials. Oncology care evolves quickly, and the reports explore potential changes in treatment practices on a global scale. Ongoing trials serve as the basis for this information as they undergo critical evaluation and may even shift depending on recently published clinical data and regulatory advances or setbacks.
The reports further identify key trends affecting care practices specific to each tumor market, discuss the potential label expansion of specific therapies, and introduce future products into the market. Additionally, reports of future insights highlight unmet needs in each cancer market, quantifying demand. In a competitive environment, these insights are prescriptive of the changing market and point to specific trends to keep an eye on.
3. Patient Metrics for Target Markets
Patient metrics are more critical than ever, as they help paint a larger picture of oncology practices by quantifying patient outcomes and exposing areas where cancer care can be improved. Clinical data, along with other financial and operational data, surrounding healthcare practices and patient metrics can be used to drive quality interventions.
Conference coverage reports analyze cancer epidemiology among patients for current and expanded markets. Epidemiology reports characterize the incidence and demographic distribution of diseases, in this case, among cancer patients, through quantitative analysis. Metrics reports usually combine epidemiologic data and expert analysis to establish context for outcomes.
Patient metrics include
• Incidence of cancer each year by stage (annual number of new cancer cases)
• Restaged 5- or 10-year prevalence (annual number of cancer patients surviving 5–10 years from diagnosis; these cases account for patients who progress to later stages)
• Number of patients by stage who are eligible for treatment, not including early stage patients in remission
• Treated patient populations categorized by modality (surgery, radiation, drug therapy), drug treatment regimens, and therapeutic agents
4. Analysis of Oncology Biomarker Segments
Cancer biomarkers are molecular processes or proteins that signify the presence of cancer; they are increasingly important in the detection and diagnosis of the disease. In fact, the discovery of biomarkers today often informs the drug development process. It’s valuable to the pharma industry to keep up with news about pertinent biomarkers and new potential indications; analysis of biomarkers can influence trends in cancer treatment as well as cancer prevention.
Biomarker segmentation helps differentiate biomarkers according to their therapeutic effects. Biomarkers are typically segmented by biomarker type (protein, genetic), by cancer type, by application (diagnostics, research, personalized medicine, etc), and by profiling technology (genomics, imaging technologies, immunoassays, bioinformatics).
Identification of biomarkers has become a priority in the development of cancer treatments, and the reports generated by an oncology conference promise the most recent information. Expert analysis of biomarkers focuses on key oncology segments and compiles all relevant conference resources, including recently published data. A thorough review of literature covers the evolving oncology landscape with regard to biomarker segmentation, and details specific demographic differences, health outcomes, and survival rates.
Busy professionals don’t have time to attend each oncology conference, or even each session or presentation. Stay on top of the newest findings surrounding cancer care with oncology insights to improve your knowledge.